Vaccine manufacturing firm GreenSignal Bio Pharma has extended its initial public offer by three days to November 17 amid lukewarm response from investors.
Book running lead managers (BRLM) to GreenSignal Bio Pharma has informed the exchange that the issue closure date has been extended up to November 17. Post issue modification date has been revised to November 18.
Till Friday the IPO, which opened for subscription on November 9, got subscribed just 82 per cent.
The offer was earlier scheduled to close on Friday.
The company has entered the capital market with its IPO of 1,45,79,560 shares of face value of Rs 10 each through an offer for sale. It has fixed the price band at Rs 76-80.
The shares are proposed to be listed on BSE and NSE.
The firm is into manufacturing of BCG vaccine given for protection against tuberculosis, mainly severe forms of child tuberculosis.
GreenSignal Bio Pharma is the 25th company to hit the market with its IPO this year.
Disclaimer: No Business Standard Journalist was involved in creation of this content
